Impact of Treatment With Colistin on Mortality Bacteremia Multiresistant Acinetobacter Baumannii Sensitive Colistin in Patients Critical

Acinetobacter Infections Clinical Trial

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02573064
• Other study ID #: FCO-COL-2015-01
• Status: Completed
• Phase: N/A
• First received: August 28, 2015
• Last updated: October 8, 2015
• Start date: January 2010

Study information

• Verified date: October 2015
• Source: Maimónides Biomedical Research Institute of Córdoba
• Contact: n/a
• Is FDA regulated: No
• Health authority: Spain: Comité Ético de Investigación Clínica
• Study type: Observational

Clinical Trial Summary

The present study was designed to study the impact of empirical treatment with colistin empirical monotherapy and combined treatment with tigecycline and vancomycin on mortality of bacteremia Multiresistant Acinetobacter Baumannii . The main objective was to evaluate the efficacy of empirical treatment with colistin and combined targeted therapy. The different therapeutical interventions were administered following the routine clinical practice in the medical centre and the investigator did not assign specific interventions to the subjects of the study.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 113
• Est. primary completion date: December 2012
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 16 Years and older

Eligibility

Inclusion Criteria:

• Critics included patients = 16 years with monomicrobial bloodstream infections by multiresistant acinetobacter baumannii to carbapenems and sensitive to colistin accompanied by systemic inflammatory response syndrome, provided they have received targeted treatment with colistin.

Study Design

Observational Model: Cohort, Time Perspective: Retrospective

Related Conditions & MeSH terms

• Acinetobacter Infections

Intervention

Drug:
• Colistin

• Tigecycline

• Vancomycin

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Maimónides Biomedical Research Institute of Córdoba

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	All-cause 30-day mortality (crude).		30 days
Secondary	All-cause 14 day mortality (crude).		14 days